Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy

HIV Medicine ◽  
2016 ◽  
Vol 18 (4) ◽  
pp. 284-291 ◽  
Author(s):  
L Milazzo ◽  
A Lai ◽  
E Calvi ◽  
P Ronzi ◽  
V Micheli ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Real Life ◽  
Life Safety ◽  
Direct Acting Antivirals ◽  
Safety And Efficacy ◽  
Direct Acting

scholarly journals PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACY

2018 ◽  
Vol 21 ◽  
pp. S143-S144
Author(s):  
L. Margusino-Framiñán ◽  
P. Cid-Silva ◽  
A. Mena-de-Cea ◽  
P. Vazquez-Rodriguez ◽  
I. Rodriguez-Osorio ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hospital Pharmacy ◽  
Public Hospital ◽  
Budget Impact ◽  
Real Life ◽  
Direct Acting Antivirals ◽  
Direct Acting

Direct-acting Antivirals for Hepatitis C Virus in Patients on Maintenance Dialysis

2017 ◽  
Vol 40 (10) ◽  
pp. 531-541 ◽  
Author(s):  
Fabrizio Fabrizi ◽  
Francesca M. Donato ◽  
Piergiorgio Messa
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Severe Renal Impairment ◽  
Controlled Trial ◽  
Hcv Infection ◽  
Direct Acting Antivirals ◽  
Safety And Efficacy ◽  
Maintenance Dialysis ◽  
Chronic Hcv ◽  
Direct Acting

The frequency of hepatitis C virus (HCV) infection remains high in patients with chronic kidney disease (CKD) and plays a detrimental role in mortality in this population. According to the latest survey, the adjusted hazard ratio for HCV-positive versus HCV-negative patients on long-term dialysis was 1.12 (95% CI, 1.05 to 1.20) and 1.10 (95% CI, 0.98 to 1.22) for all-cause and cardiovascular mortality, respectively. An impairment on quality of life has also been documented in HCV-infected patients undergoing regular dialysis. Most clinicians have been so far reluctant to treat hepatitis C in patients with advanced CKD, due to concerns regarding low efficacy and safety of interferon-based regimens. The advent of all-oral, direct-acting antivirals (DAAs) has revolutionized treatment paradigms for HCV, including patients with other comorbidities such as CKD. Two combinations of DAAs have been recently approved for the treatment of HCV in advanced CKD: elbasvir/grazoprevir (evaluated in 1 randomized controlled trial) and ombitasvir/paritaprevir/ritonavir/dasabuvir with or without ribavirin (examined in some observational, single-arm studies). These antiviral combinations have provided high safety and efficacy (SVR12 rates >90%) in HCV-infected patients with stage 4–5 CKD. Sofosbuvir, a nucleotide analogue inhibitor of the HCV NS5B polymerase, is the cornerstone of most anti-HCV current regimens but is not currently recommended for patients with severe renal insufficiency (eGFR <30 mL/min per 1.73 m2). However, several small-sized studies have been published on the safety and efficacy of sofosbuvir-based regimens for patients with hepatitis C on maintenance dialysis>; overall, the viral response was satisfactory (SVR12 rates ranging between 58% and 100%) with a few drug-related drop-outs. Studies are in progress to assess whether ribavirin-free antiviral combinations with novel DAAs are a viable option for patients with severe renal impairment and chronic HCV infection.

Direct Acting Antivirals in patients with HCV-associated mixed cryoglobulinemia: real life safety and efficacy

2017 ◽  
Vol 66 (1) ◽  
pp. S503
Author(s):  
G. Rizzardini ◽  
M. Schiavini ◽  
F. Niero ◽  
C. Magni ◽  
S. Landonio ◽  
...  
Keyword(s):  
Real Life ◽  
Mixed Cryoglobulinemia ◽  
Life Safety ◽  
Direct Acting Antivirals ◽  
Safety And Efficacy ◽  
Direct Acting

Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.

2021 ◽  
Author(s):  
Eric Kauffman-Ortega ◽  
Jesus Ruiz-Manriquez ◽  
Antonio Olivas-Martinez ◽  
Alejandro Campos-Murguía ◽  
Nayelli C Flores-García ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Life Experience ◽  
Real Life ◽  
Direct Acting Antivirals ◽  
Direct Acting

Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection

2019 ◽  
Vol 14 (3) ◽  
pp. 173-182 ◽  
Author(s):  
Riccardo Scotto ◽  
Antonio Riccardo Buonomo ◽  
Nicola Schiano Moriello ◽  
Alberto Enrico Maraolo ◽  
Emanuela Zappulo ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Adverse Reactions ◽  
Safety Data ◽  
Real Life ◽  
Efficacy And Safety ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Very High

Background: Advances in the development of Direct-Acting Antivirals (DAAs), particularly pangenotypic drugs, have led to a high rate of hepatitis C virus (HCV) eradication. Notably, real- world studies have confirmed the efficacy and safety of pangenotypic DAA combinations reported in registration trials. The aim of this study was to review the treatment recommendations, and the efficacy and safety data of anti-HCV pangenotypic drugs reported in registration clinical trials and in recent real-life cohort studies. Methods: We reviewed the efficacy and safety data of pangenotypic anti-HCV drug combinations reported in original articles and in online conference abstracts. Results: Current pangenotypic drug combinations resulted in very high rates of sustained virologic response and few adverse reactions in real-life settings. SVR12 rates in real-life studies ranged from 90-100% depending on the pangenotypic combination, the HCV genotype and the stage of liver disease. Most adverse reactions reported in real-life settings were mild in intensity and rarely led to treatment discontinuation. These results are in accordance with those of clinical trials. Conclusion: Pangenotypic DAAs result in very high rates of sustained virologic responses and are well tolerated. However, they are contraindicated in patients with decompensated cirrhosis or advanced chronic kidney disease who failed previous DDA-based treatment. Further research is required to customize treatment to “unpackage” current DAA combinations and to develop generic drugs against HCV.

Sign in / Sign up

Export Citation Format

Share Document